TY  - JOUR

T1  - Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

JO  - Pharmacoeconomics

UR  - https://eprints.whiterose.ac.uk/id/eprint/117002

UR  - https://doi.org/10.1007/s40273-017-0521-5

PY  - 2017/11/01

AU  - Bermejo I

AU  - Stevenson M

AU  - Archer R

AU  - Stevens JW

AU  - Goka E

AU  - Clowes M

AU  - Scott DL

AU  - Young A

ED  - 

DO  - DOI: 10.1007/s40273-017-0521-5

PB  - Springer Verlag

VL  - 35

IS  - 11

SP  - 1141

EP  - 1151

Y2  - 2025/11/05

ER  -